We're thrilled to share that CRISPR Therapeutics will ring the Opening Bell this morning at the Nasdaq MarketSite Studio in Times Square. We’re excited to commemorate the historic first-ever approval of a CRISPR-based therapy and celebrate innovation as we continue to expand and advance our programs for rare and common diseases. Join us by tuning in for the livestream here starting at 9:15am ET: https://lnkd.in/eJz78vY
👏👏👏 well deserved
Fantastic!!!!!
Understand the natural course of ADPKD and Cystic Fibrosis (CF) programs with scalable assays and validated models for ADPKD and CF. With a customized set-up that can accommodate your research needs, our screening platforms enable investigation of phenotypic changes in in vitro and ex vivo models. Discover more ➡️ https://bit.ly/3pNIzbX #ADPKD #Inflammation #CysticFibrosis
#SpeakingofScience: Hats off to Annette Bakker and our friends at Children's Tumor Foundation for this great article in STAT! This piece discusses the meaningful nuances between “drug repurposing” and “drug repositioning.” The former uses an existing drug to treat a new condition, while the latter uses an existing drug to treat a new indication of a known condition. This important distinction is one that demands increased awareness, as it may affect the regulatory pathway for new treatments. #medicaltreatments #medicalresearch #drugdevelopment #clinicalresearch https://lnkd.in/gUDa9Bhk
#WhitepaperWednesday is a series that highlights in-depth discussions that inform, educate and explore critical topics, groundbreaking research and more. We invite you to download "NeoGenomics minimal residual disease (MRD) testing, A diagnostic/prognostic clinical indicator as well as a biomarker/endpoint in novel drug development." Read it online today: http://ow.ly/o7MU104smwt #whitepaper #NeoGenomics
Need a cost-effective and time-efficient syngeneic platform to fast-track your in vivo preclinical immunotherapy development? MuScreen™ helps you rapidly identify the right markers and models for your preclinical programs improving efficiency and saving study time. Why screen your immunotherapy and immune modulating compounds with MuScreen? ✅Well-characterized syngeneic and tumor homograft (MuPrime™) models ✅Suitable for single agent and combination regimens ✅Cost effective (discount on shared control groups, cost of vehicle group covered) ✅Time efficient (quickly identify responder models or markers) Don’t miss out. Our next 6 Model Syngeneic Efficacy and PD Mode screen is coming up soon. ⏰Registration closes August 11, 2023. ➡️ https://bit.ly/3YiXAiJ #InVivo #DrugDevelopment #Immunotherapy
What does the new era of Parkinson’s research mean, and what’s next — for research, and for those living with the disease? From the new biomarker for PD to new therapeutics accelerating through the clinical pipeline, it’s a year like no other for Parkinson’s research. Tune into this upcoming webinar from The Michael J. Fox Foundation for Parkinson's Research to learn why this year is transformative — and why we’re entering a new era. #SlowStopCureParkinsons #ParkinsonsResearch #LivingWithParkinsons
VP, Research Informatics at Alnylam Pharmaceuticals
3wDefinitely hold the bell with your left hand..... ;)